Methods for treatment of motor neuron diseases
The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associated with motor neuron diseases are also provided.
1. A method of ameliorating weight loss of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby ameliorating the subject with ALS loss of weight.
2. A method of reducing muscle atrophy of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby reducing muscle atrophy of the subject with ALS.
3. A method of preserving muscle strength of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby preserving muscle strength of the subject with ALS.
4. A method of reducing nerve demyelination of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby reducing nerve demyelination of the subject with ALS.
5. A method of reducing disease progression of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby reducing disease progression of the subject with ALS.
6. A method of reducing loss of movement of a subject with amyotrophic lateral sclerosis (ALS), the method comprising administering to a subject in need thereof an effective amount of an anti-CTGF antibody that has the same amino acid sequence as the antibody produced by the cell line identified by ATCC Accession No. PTA-6006, thereby reducing loss of movement of the subject with ALS.
7. The method of any one of claims 1 - 6 , wherein the effective amount of the anti-CTGF antibody is at least 10 mg/kg.
8. The method of claim 7 , further comprising the administration of riluzole.